Evaluation of the nitrate reductase assay for rapid detection of extensively drug-resistant tuberculosis

被引:0
|
作者
Rosales, S. [1 ,2 ,3 ]
Pineda-Garcia, L. [2 ]
Andino, N. [2 ,4 ]
Almendarez, N. [4 ]
Membreno, H. [4 ]
Hoffner, S. E. [1 ]
机构
[1] Swedish Inst Infect Dis Control, Dept Bacteriol, S-17182 Solna, Sweden
[2] Univ Nacl Autonoma Honduras, Dept Microbiol, Tegucigalpa, Honduras
[3] Karolinska Inst, Dept Publ Hlth Sci, Div Int Hlth, Stockholm, Sweden
[4] Secretaria Salud, Lab Nacl Referencia TB, Tegucigalpa, Honduras
关键词
Mycobacterium tuberculosis; MDR-TB; XDR-TB; drug susceptibility testing; NRA; MYCOBACTERIUM-TUBERCULOSIS; SPUTUM SAMPLES; RIFAMPIN; RESAZURIN;
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BACKGROUND: New diagnostic tools are needed to support tuberculosis (TB) control strategies, particularly in low- and middle-income countries with a high prevalence of TB. OBJECTIVE: To evaluate the nitrate reductase assay (NRA) for the rapid detection of resistance to isoniazid (INH) and rifampicin (RMP), as well as to second-line drugs such as ofloxacin (OFX) and kanamycin (KM). DESIGN: To determine diagnostic accuracy, 192 selected clinical isolates of Mycobacterium tuberculosis were used to compare NRA with BACTEC(TM) 460TB for rapid detection of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB strains. RESULTS: A good agreement between NRA and the BACTEC 460TB reference method was observed, with good sensitivity and excellent specificity for INH, RMP and OFX. Results for KM were also promising, although the sensitivity for the detection of KM resistance should be improved. CONCLUSION: NRA is a diagnostic tool of promise for the timely detection of M. tuberculosis resistance to first- and second-line drugs. Our study showed a clear potential for the prompt detection of both MDR- and XDR-TB cases. Further studies are needed to optimise the testing of second-line drugs.
引用
收藏
页码:1542 / 1549
页数:8
相关论文
共 50 条
  • [21] Extensively drug-resistant tuberculosis, Taiwan
    Yu, Ming-Chih
    Wu, Mei-Hua
    Jou, Ruwen
    EMERGING INFECTIOUS DISEASES, 2008, 14 (05) : 849 - 850
  • [22] Extensively drug-resistant tuberculosis, Lesotho
    Satti, Hind
    Seung, Kwonjune
    Keshavjee, Salmaan
    Furin, Jennifer
    EMERGING INFECTIOUS DISEASES, 2008, 14 (06) : 992 - 993
  • [23] Treatment of extensively drug-resistant tuberculosis
    Silva, Jussara Munareto
    Fuchs, Sandra C.
    Barcellos, Nemora T.
    Zavascki, Alexandre P.
    LANCET, 2009, 373 (9657): : 27 - 27
  • [24] Extensively drug-resistant tuberculosis in India
    John, T. Jacob
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2010, 131 (01) : 109 - 110
  • [25] Extensively Drug-Resistant Tuberculosis Reply
    Mitnick, Carole D.
    Bayona, Jaime
    Becerra, Mercedes C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (22): : 2391 - 2391
  • [26] Extensively Drug-Resistant Tuberculosis, Pakistan
    Hasan, Rumina
    Jabeen, Kauser
    Ali, Asho
    Rafiq, Yasraba
    Laiq, Rabia
    Malik, Babar
    Tanveer, Mahnaz
    Groenheit, Ramona
    Ghebremichael, Solomon
    Hoffner, Sven
    Hasan, Zahra
    EMERGING INFECTIOUS DISEASES, 2010, 16 (09) : 1473 - 1475
  • [27] Controlling extensively drug-resistant tuberculosis
    Porco, Travis C.
    Getz, Wayne M.
    LANCET, 2007, 370 (9597): : 1464 - 1465
  • [28] Multidrug and extensively drug-resistant tuberculosis
    Maitre, T.
    Aubry, A.
    Jarlier, V.
    Robert, J.
    Veziris, N.
    Bernard, C.
    Sougakoff, W.
    Brossier, F.
    Cambau, E.
    Mougari, F.
    Raskine
    MEDECINE ET MALADIES INFECTIEUSES, 2017, 47 (01): : 3 - 10
  • [29] Update on extensively drug-resistant tuberculosis
    Elgin, Nancy
    AMERICAN JOURNAL OF NURSING, 2007, 107 (06) : 19 - 19
  • [30] The threat of extensively drug-resistant tuberculosis
    Mohapatra, Prasanta Raghab
    CLINICAL INFECTIOUS DISEASES, 2007, 44 (06) : 888 - 889